- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
51 result(s) found for: Reference material.
Displaying page 3 of 3.
EudraCT Number: 2013-004879-13 | Sponsor Protocol Number: UKF2013/12 | Start Date*: 2014-12-08 | |||||||||||||||||||||
Sponsor Name:Universitätsklinikum Freiburg | |||||||||||||||||||||||
Full Title: α-RT; Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. EBRT alone in the treatment of advanced castr... | |||||||||||||||||||||||
Medical condition: Bone metastases in advanced castration resistant prostate carcinoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020408-31 | Sponsor Protocol Number: I2I-MC-JMMG | Start Date*: 2010-11-10 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company | ||||||||||||||||||
Full Title: A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed and Cisplatin in Patients with Stage IV Non-small Cell Lung Cancer | ||||||||||||||||||
Medical condition: • Histological diagnosis of Stage IV NSCLC other than predominantly squamous cell histology. • Mesothelioma in advanced or metastatic stage for whom the combination with pemetrexed and cisplatin i... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000148-40 | Sponsor Protocol Number: PDSTAT2015 | Start Date*: 2015-11-09 | ||||||||||||||||
Sponsor Name:Plymouth Hospitals NHS Trust | ||||||||||||||||||
Full Title: Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity. | ||||||||||||||||||
Medical condition: Parkinson's disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005703-39 | Sponsor Protocol Number: IB2020-05 | Start Date*: 2021-07-27 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. | |||||||||||||
Medical condition: soft-tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003385-14 | Sponsor Protocol Number: AROAAT2001 | Start Date*: 2019-08-06 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficie... | |||||||||||||
Medical condition: alpha-1 antitrypsin deficiency (AATD)-associated liver disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) SE (Completed) ES (Restarted) GB (GB - no longer in EU/EEA) PT (Completed) NL (Ongoing) DE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003957-10 | Sponsor Protocol Number: SCOT-2007-01 | Start Date*: 2011-01-31 | ||||||||||||||||
Sponsor Name:Greater Glasgow Health Board (GGHB)/ University of Glasgow | ||||||||||||||||||
Full Title: Short Course Oncology Therapy - A study of adjuvant chemotherapy in colorectal cancer | ||||||||||||||||||
Medical condition: Colorectal Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DK (Completed) ES (Completed) SE (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003398-51 | Sponsor Protocol Number: R-Pola-Glo | Start Date*: 2023-03-05 | |||||||||||
Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest | |||||||||||||
Full Title: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in... | |||||||||||||
Medical condition: aggressive large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000037-14 | Sponsor Protocol Number: NEOD001-301 | Start Date*: 2021-09-01 | |||||||||||
Sponsor Name:Prothena Biosciences Limited | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with ... | |||||||||||||
Medical condition: AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002766-39 | Sponsor Protocol Number: ET13-002 | Start Date*: 2021-02-17 | |||||||||||
Sponsor Name:Centre Leon Berard | |||||||||||||
Full Title: SIOP Ependymoma II - An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma | |||||||||||||
Medical condition: Newly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellular, papillary, myxopapillary, clear-cell and tanycytic) or anaplastic ependymoma. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) IE (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000556-26 | Sponsor Protocol Number: C-700-01 | Start Date*: 2018-02-27 | |||||||||||
Sponsor Name:Agenus Inc. | |||||||||||||
Full Title: A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Loca... | |||||||||||||
Medical condition: Metastatic or Locally Advanced Solid Tumors and Cervical Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) EE (Completed) ES (Prematurely Ended) BE (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001040-62 | Sponsor Protocol Number: GBG78/BIG1-13 | Start Date*: 2013-11-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse r... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: About one-third of patient with hormone-receptor positive, HER2 negative breast cancer and residual disease after standard of care - including adequate surgery - have a substantial risk of relapse ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) AT (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
